AVTX

Healthcare Biotechnology

Avalo Therapeutics, Inc.

$14.99

-0.22 -1.45% today

Price History

Not enough data

Key Stats

Market Cap

803.91M

Avg Volume

956,515

EPS

-$4.42

52W High

$24.27

52W Low

$12.51

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-5.47

P/B Ratio

1.77

P/S Ratio

13625.65

EV/EBITDA

-4.43

EV/Revenue

6845.42

Margins

Gross Margin 0.0%

Operating Margin (154847.5%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(36.3%)

Return on Assets

(18.5%)

Liquidity & Leverage

Current Ratio

19.31

Quick Ratio

18.94

Debt / Equity

0.00

Total Cash

400.28M

Total Debt

242,000

About

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.